The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience

BACKGROUND: Rituximab, a monoclonal antibody directed against CD20, is approved for the treatment of CD20-positive B-cell Non-Hodgkin’s lymphoma and rheumatologic disorders. Due to its potent activity in depleting CD20-positive lymphocytes, the influence on opportunistic infections is still under di...

Descripción completa

Detalles Bibliográficos
Autores principales: Nissen, Johanna C, Hummel, Margit, Brade, Joachim, Kruth, Jens, Hofmann, Wolf-Karsten, Buchheidt, Dieter, Reinwald, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227097/
https://www.ncbi.nlm.nih.gov/pubmed/24992940
http://dx.doi.org/10.1186/1471-2334-14-364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227097/
https://www.ncbi.nlm.nih.gov/pubmed/24992940
http://dx.doi.org/10.1186/1471-2334-14-364

Ejemplares similares